PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
unknown
📅 Published: 2026-03-18 15:24
📰 Source: Yahoo
📝 Words: 20
📝 Article Content
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
📄 Summary
Pfizer's phase II study evaluating CDK4 inhibitor, atirmociclib, in 2L metastatic breast cancer meets primary endpoint. Supports oncology pipeline progress.
Scraping Metadata:
Scraped At:
Unknown
Created At:
2026-03-20 04:09:39
Updated At:
2026-03-20 04:09:39
Scraping Job ID:
N/A
Stock Mentions:
PFE - Pfizer Inc.
Relevance: N/A